LIORESAL INTRATHECAL 0.5MG/ML 0.5 MG
BACLOFEN : 0.5 MG · DIN 02131056 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: CANCELLED POST MARKET
What is LIORESAL INTRATHECAL 0.5MG/ML?
LIORESAL INTRATHECAL 0.5MG/ML 0.5 MG contains BACLOFEN : 0.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02131056, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as SOLUTION for INTRATHECAL administration. Health Canada currently lists it as cancelled post market, status dated 28-Aug-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LIORESAL INTRATHECAL 0.5MG/ML used for?
Management of severe spasticity due to spinal cord injury or multiple sclerosis unresponsive to oral baclofen or with unacceptable side effects. Alternative to neurosurgical procedures.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is LIORESAL INTRATHECAL 0.5MG/ML called?
The same molecule, BACLOFEN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| APO-Baclofen | Latin | Australia |
| Baclon | Latin | Bahrain, Saudi Arabia |
| Sintetica Baclofen Intrathecal | Latin | Australia |
| BACLOCALM | Latin | Bahrain |
| Bacthecal | Latin | Australia |
| Bastix | Latin | Saudi Arabia |
| Lioresal | Latin | Bahrain, South Africa |
| Lioresal Intrathecal | Latin | Australia |
| Loanta | Latin | Bahrain, Saudi Arabia |
| baclocan | Latin | Saudi Arabia |
| Baclofen | Latin | Saudi Arabia |
| Baclofen Crescent | Latin | Saudi Arabia |
| Bio-Baclofen | Latin | South Africa |
| Fenozyd | Latin | South Africa |
| Spasifen | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02131056 |
|---|---|
| Brand name | LIORESAL INTRATHECAL 0.5MG/ML |
| Generic / active ingredient | BACLOFEN : 0.5 MG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 0.5 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRATHECAL |
| Schedule | Prescription |
| ATC code | M03BX01 BACLOFEN |
| AHFS class | 12:20.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 28-Aug-2023 |
| Original market date | 1994-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02131056 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2131056 |
| Brand name | LIORESAL INTRATHECAL 0.5MG/ML |
| Active ingredient / INN | BACLOFEN : 0.5 MG |
| ATC code | M03BX01 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M03 |
| AHFS class | 12:20.12 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | NOVARTIS PHARMACEUTICALS CANADA INC |
How is it administered?
Must be administered via screening trial (bolus) before pump implantation. Chronic infusion via implantable pump. Titrate gradually to maintain effectiveness. Requires medical supervision.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text.
How is it supplied?
Not explicitly detailed in provided text (mentions 0.05 mg/mL, 0.5 mg/mL and 2 mg/mL concentrations).
Which pack is which?
| Strength on the label | 0.5 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRATHECAL |
| Packaging as described in the monograph | Not explicitly detailed in provided text (mentions 0.05 mg/mL, 0.5 mg/mL and 2 mg/mL concentrations). |
| Storage | Not explicitly detailed in provided text. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Known or suspected hypersensitivity to baclofen or any excipients. Not for intravenous, intramuscular, subcutaneous, or epidural administration.
Warnings and precautions
Risk of life-threatening CNS depression, cardiovascular collapse, respiratory failure. Abrupt withdrawal can cause high fever, altered mental status, rebound spasticity, and death.
Is BACLOFEN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Discontinued — reported by AVIR PHARMA INC., last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code M03BX01 BACLOFEN. 23 of 59 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-BACLOFEN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02139332 |
| APO-BACLOFEN | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02139391 |
| BACLOFEN | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02287021 |
| BACLOFEN | 10 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02544660 |
| BACLOFEN | 20 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02287048 |
| BACLOFEN | 20 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02544679 |
| BACLOFEN INJECTION | 0.05 MG / 1 ML | SOLUTION | STERIMAX INC | MARKETED | DIN 02413620 |
| BACLOFEN INJECTION | 10 MG / 20 ML | SOLUTION | STERIMAX INC | MARKETED | DIN 02413639 |
| BACLOFEN INJECTION | 10 MG / 5 ML | SOLUTION | STERIMAX INC | MARKETED | DIN 02413647 |
| BACLOFEN INJECTION | 2 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02457075 |
Who else supplies BACLOFEN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BACLOFEN appears in 174 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does BACLOFEN cost around the world?
BACLOFEN is listed on 10 national price registers Nexara tracks, across 208 pack listings published on 8 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 7 | 127 | 03 Sep 2026 |
| Australia | ex-manufacturer | 10 | 24 | 08 Sep 2026 |
| Saudi Arabia | public | 11 | 14 | 01 Sep 2026 |
| South Africa | single exit price | 12 | 13 | 01 Sep 2026 |
| United Kingdom | hospital | 7 | 7 | 31 Aug 2026 |
| Bahrain | retail (max) | 4 | 6 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 5 | 5 | 03 Sep 2026 |
| United Arab Emirates | public | 4 | 4 | 31 Aug 2026 |
| Hungary | producer price (ex-factory) | 4 | 4 | 03 Sep 2026 |
| Romania | max producer price | 2 | 4 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.